KY102
/ Hangzhou Kunyu Pharmaceutical
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 18, 2026
KY102, a novel Glypican 3-targeting nanobody drug conjugate bearing a topoisomerase 1 inhibitor payload demonstrates compelling preclinical activity in hepatocellular carcinoma models
(AACR 2026)
- "Overall, these results support the potential of KY102 as a novel therapeutic agent against GPC3-bearing cancers including HCC. An IND application is anticipated in 2026. No conflict of interest"
Preclinical • Hepatocellular Cancer • Oncology • Solid Tumor • GPC3
1 to 1
Of
1
Go to page
1